Incidations for thalidomide therapy for leprosy.
D002462:Cell Membrane / Q000187:drug effects; D003622:Dapsone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004790:Enzyme Induction / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007918:Leprosy / Q000188:drug therapy*; D008213:Lymphocyte Activation / Q000187:drug effects; D008247:Lysosomes / Q000187:drug effects; D008264:Macrophages / Q000187:drug effects; D008297:Male; D013421:Sulfamethoxypyridazine / Q000627:therapeutic use; D013792:Thalidomide / Q000494:pharmacology / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D013792:Thalidomide; D003622:Dapsone; D013421:Sulfamethoxypyridazine